1
|
Kumar D, Oberoi HS, Singh H, Shrivastav TG, Bhukya PL, Kumari M, Koner BC, Sonkar SC. Development and optimization of an in-house heterologous ELISA for detection of prednisolone drug in enzyme conjugates using spacers. Front Immunol 2023; 14:1200328. [PMID: 37675116 PMCID: PMC10477981 DOI: 10.3389/fimmu.2023.1200328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 07/20/2023] [Indexed: 09/08/2023] Open
Abstract
The introduction of spacers in coating steroid protein complexes and/or enzyme conjugates or immunogens is known to exert an influence on the sensitivity of steroid enzyme immunoassays. We investigated the impact of different homobifunctional spacers, ranging in atomic length from 3 to 10, on the sensitivity and specificity of prednisolone (PSL) enzyme immunoassays. In this study, four homo-bifunctional spacers, namely, carbohydrazide (CH), adipic acid dihydrazide (ADH), ethylene diamine (EDA), and urea (U), were incorporated between PSL and horseradish peroxidase (HRP) for preparing the enzyme conjugate with an aim to improve the sensitivity of the assay without compromising assay specificity. The assays were developed using these enzymes conjugated with antibodies raised against the PSL-21-HS-BSA immunogen. The sensitivity of the PSL assays after insertion of a bridge in the enzyme conjugate was 1.22 ng/mL, 0.59 ng/mL, 0.48 ng/mL, and 0.018 ng/mL with ADH, CH, EDA, and urea as a spacer, respectively. Among the four combinations, the PSL-21-HS-BSA-antibody with PSL-21-HS-U-HRP-enzyme conjugate gave better sensitivity and less cross-reaction. The percent recovery of PSL from the exogenously spiked human serum pools was in the range of 88.32%-102.50%. The intra and inter-assay CV% was< 8.46%. The PSL concentration was estimated in the serum samples of patients on PSL treatment. The serum PSL values obtained by this method correlated well with the commercially available kit (r2 = 0.98). The present study suggests that the nature of the spacer is related to assay sensitivity and not the spacer length.
Collapse
Affiliation(s)
- Dinesh Kumar
- Department of Reproductive Biomedicine, National Institute of Health and Family Welfare (NIHFW), New Delhi, India
- Quality Assurance Division, Food Safety and Standards Authority of India (FSSAI), New Delhi, India
| | - Harinder Singh Oberoi
- Quality Assurance Division, Food Safety and Standards Authority of India (FSSAI), New Delhi, India
| | - Harpal Singh
- Centre for Biomedical Engineering, Indian Institute of Technology Delhi (IIT-D), New Delhi, India
- Department of Biomedical Engineering, All India Institute of Medical Sciences Delhi (AIIMS-D), New Delhi, India
| | - Tulsidas G. Shrivastav
- Department of Reproductive Biomedicine, National Institute of Health and Family Welfare (NIHFW), New Delhi, India
| | - Prudhvi Lal Bhukya
- Rodent Experimentation Facility, Indian Council of Medical Research (ICMR)-National Animal Resource Facility for Biomedical Research (Indian Council of Medical Research (ICMR)-NARFBR), Hyderabad, India
| | - Mansi Kumari
- Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pune, India
| | - Bidhan Chandra Koner
- Multidisciplinary Research Unit, Maulana Azad Medical College and Associated Hospital, New Delhi, India
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospital, New Delhi, India
| | - Subash Chandra Sonkar
- Multidisciplinary Research Unit, Maulana Azad Medical College and Associated Hospital, New Delhi, India
- Delhi School of Public Health, Institute of Eminence, University of Delhi, Delhi, India
| |
Collapse
|
2
|
Torrents de la Peña A, Sewall LM, de Paiva Froes Rocha R, Jackson AM, Pratap PP, Bangaru S, Cottrell CA, Mohanty S, Shaw AC, Ward AB. Increasing sensitivity of antibody-antigen interactions using photo-cross-linking. Cell Rep Methods 2023; 3:100509. [PMID: 37426749 PMCID: PMC10326447 DOI: 10.1016/j.crmeth.2023.100509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Revised: 04/12/2023] [Accepted: 05/30/2023] [Indexed: 07/11/2023]
Abstract
Understanding antibody-antigen interactions in a polyclonal immune response in humans and animal models is critical for rational vaccine design. Current approaches typically characterize antibodies that are functionally relevant or highly abundant. Here, we use photo-cross-linking and single-particle electron microscopy to increase antibody detection and unveil epitopes of low-affinity and low-abundance antibodies, leading to a broader structural characterization of polyclonal immune responses. We employed this approach across three different viral glycoproteins and showed increased sensitivity of detection relative to currently used methods. Results were most noticeable in early and late time points of a polyclonal immune response. Additionally, the use of photo-cross-linking revealed intermediate antibody binding states and demonstrated a distinctive way to study antibody binding mechanisms. This technique can be used to structurally characterize the landscape of a polyclonal immune response of patients in vaccination or post-infection studies at early time points, allowing for rapid iterative design of vaccine immunogens.
Collapse
Affiliation(s)
- Alba Torrents de la Peña
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Leigh M. Sewall
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Rebeca de Paiva Froes Rocha
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Abigail M. Jackson
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Payal P. Pratap
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Sandhya Bangaru
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Christopher A. Cottrell
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Subhasis Mohanty
- Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA
| | - Albert C. Shaw
- Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA
| | - Andrew B. Ward
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| |
Collapse
|
3
|
Alderete JF. Advancing Prevention of STIs by Developing Specific Serodiagnostic Targets: Trichomonas vginalis as a Model. Int J Environ Res Public Health 2020; 17:E5783. [PMID: 32785073 DOI: 10.3390/ijerph17165783] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 08/03/2020] [Accepted: 08/06/2020] [Indexed: 12/24/2022]
Abstract
Point-of-Care (POC) serum antibody screening of large cohorts of women and men at risk for the sexually transmitted infection (STI) caused by Trichomonas vaginalis requires the availability of targets with high specificity. Such targets should comprise epitopes unique to T. vaginalis immunogenic proteins detected by sera of women and men patients with trichomonosis but not uninfected controls. Three enzymes to which patients make serum IgG antibody were identified as fructose-1,6-bisphosphate aldolase (A), α-enolase (E), and glyceraldehyde-3-phosphate dehydrogenase (G). Epitopes within these proteins were identified that had no sequence identity to enzymes of humans and other pathogens. Therefore, I constructed a chimeric recombinant String-Of-Epitopes (SOE) protein consisting of 15-mer peptides, within which are the epitopes of A, E, and G. This novel protein of ~36-kD is comprised of two epitopes of A, ten epitopes of E, and seven epitopes of G (AEG::SOE2). The AEG::SOE2 protein was detected both by immunoblot and by enzyme-linked immunosorbent assay (ELISA) using highly reactive sera of women and men but not negative serum unreactive to T. vaginalis proteins. Finally, AEG::SOE2 was found to be immunogenic, as evidenced by serum IgG from immunized mice. I discuss how this approach is important in relation to infectious disease diagnostic targets for detection of serum IgG antibody in exposed and/or infected individuals and how such novel targets may have potential as subunit vaccine candidates against microbial pathogens.
Collapse
|
4
|
Shacklett BL, Blanco J, Hightow-Weidman L, Mgodi N, Alcamí J, Buchbinder S, Chirenje M, Dabee S, Diallo M, Dumchev K, Herrera C, Levy ME, Martin Gayo E, Makoah NA, Mitchell KM, Mugwanya K, Reddy K, Rodríguez ML, Rodriguez-Garcia M, Shover CL, Shrivastava T, Tomaras G, Van Diepen M, Walia M, Warren M, Manrique A, Thyagarajan B, Torri T. HIV Research for Prevention 2018: From Research to Impact Conference Summary and Highlights. AIDS Res Hum Retroviruses 2019; 35:598-607. [PMID: 31007035 PMCID: PMC6602109 DOI: 10.1089/aid.2019.0074] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
The HIV Research for Prevention (HIVR4P) conference is dedicated to advancing HIV prevention research, responding to a growing consensus that effective and durable prevention will require a combination of approaches as well as unprecedented collaboration among scientists, practitioners, and community workers from different fields and geographic areas. The conference theme in 2018, "From Research to Impact," acknowledged an increasing focus on translation of promising research findings into practical, accessible, and affordable HIV prevention options for those who need them worldwide. HIVR4P 2018 was held in Madrid, Spain, on 21-25 October, with >1,400 participants from 52 countries around the globe, representing all aspects of HIV prevention research and implementation. The program included 137 oral and 610 poster presentations. This article presents a brief summary of highlights from the conference. More detailed information, complete abstracts as well as webcasts and daily Rapporteur summaries may be found on the conference website.
Collapse
Affiliation(s)
- Barbara L. Shacklett
- Medical Microbiology and Immunology, University of California, Davis, Davis, California
| | - Julià Blanco
- IrsiCaixa, IGTP, Barcelona, Spain
- Chair in AIDS and Related Illnesses, Centre for Health and Social Care Research (CESS), Faculty of Medicine, University of Vic-UCC, Barcelona, Spain
| | - Lisa Hightow-Weidman
- Division of Infectious Diseases, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina
| | - Nyaradzo Mgodi
- University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
| | - José Alcamí
- AIDS Immunopathology Unit, Instituto de Salud Carlos III, Madrid, Spain
| | - Susan Buchbinder
- San Francisco Department of Public Health, San Francisco, California
| | - Mike Chirenje
- University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
| | - Smritee Dabee
- Division of Medical Virology, University of Cape Town, Cape Town, South Africa
| | - Mamadou Diallo
- Department of Social and Preventive Medicine, University Laval, Quebec, Canada
| | | | - Carolina Herrera
- Faculty of Medicine, Department of Medicine, Imperial College London, London, United Kingdom
| | - Matthew E. Levy
- Department of Epidemiology and Biostatistics, The George Washington University, Washington, District of Columbia
| | - Enrique Martin Gayo
- Immunology Department, Hospital Universitario La Princesa, Universidad Autónoma de Madrid, Madrid, Spain
| | - Nigel Aminake Makoah
- Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa
| | - Kate M. Mitchell
- MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom
- HPTN Modelling Centre, Imperial College London, London, United Kingdom
| | - Kenneth Mugwanya
- Department of Epidemiology, University of Washington, Seattle, Washington
| | - Krishnaveni Reddy
- Wits Reproductive Health and HIV Institute, University of the Witwatersrand, School of Clinical Medicine, Johannesburg, South Africa
| | | | - Marta Rodriguez-Garcia
- Department of Physiology and Neurobiology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire
| | - Chelsea L. Shover
- Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California
| | - Tripti Shrivastava
- Department of Infection and Immunology, Translational Health Science and Technology Institute, Faridabad, India
| | - Georgia Tomaras
- Departments of Surgery, Immunology, and Molecular Genetics and Microbiology, Duke University, Durham, North Carolina
| | - Michiel Van Diepen
- Division of Medical Virology, University of Cape Town, Cape Town, South Africa
| | | | | | | | | | | |
Collapse
|
5
|
Gaudreault NN, Richt JA. Subunit Vaccine Approaches for African Swine Fever Virus. Vaccines (Basel) 2019; 7:vaccines7020056. [PMID: 31242632 PMCID: PMC6631172 DOI: 10.3390/vaccines7020056] [Citation(s) in RCA: 79] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2019] [Revised: 06/21/2019] [Accepted: 06/21/2019] [Indexed: 12/14/2022] Open
Abstract
African swine fever virus (ASFV) is the cause of a highly fatal disease in swine, for which there is no available vaccine. The disease is highly contagious and poses a serious threat to the swine industry worldwide. Since its introduction to the Caucasus region in 2007, a highly virulent, genotype II strain of ASFV has continued to circulate and spread into Eastern Europe and Russia, and most recently into Western Europe, China, and various countries of Southeast Asia. This review summarizes various ASFV vaccine strategies that have been investigated, with focus on antigen-, DNA-, and virus vector-based vaccines. Known ASFV antigens and the determinants of protection against ASFV versus immunopathological enhancement of infection and disease are also discussed.
Collapse
Affiliation(s)
- Natasha N Gaudreault
- Department of Diagnostic Medicine & Pathobiology, College of Veterinary Medicine, Kansas State University, K224 Mosier Hall, 1800 Denison Ave, Manhattan, KS 66506, USA.
| | - Juergen A Richt
- Department of Diagnostic Medicine & Pathobiology, College of Veterinary Medicine, Kansas State University, K224 Mosier Hall, 1800 Denison Ave, Manhattan, KS 66506, USA.
| |
Collapse
|
6
|
Abstract
BACKGROUND A vaccine able to elicit broadly neutralizing antibodies capable of blocking infection by global viruses has not been achieved, and remains a key public health challenge. OBJECTIVE During infection, a robust strain-specific neutralizing response develops in most people, but only a subset of infected people develop broadly neutralizing antibodies. Understanding how and why these broadly neutralizing antibodies develop has been a focus of the HIV-1 vaccine field for many years, and has generated extraordinary insights into the neutralizing response to HIV-1 infection. RESULTS This review describes the features, targets and developmental pathways of early strainspecific antibodies and later broadly neutralizing antibodies, and explores the reasons such broad antibodies are not more commonly elicited during infection. CONCLUSION The insights from these studies have been harnessed for the development of pioneering new vaccine approaches that seek to drive B cell maturation towards breadth. Overall, this review describes how findings from infected donors have impacted on active and passive immunization approaches that seek to prevent HIV-1 infection.
Collapse
Affiliation(s)
- Penny L Moore
- Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.,Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.,Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa
| |
Collapse
|
7
|
Wang Y, Wang E, He Y, Wang K, Yang Q, Wang J, Geng Y, Chen D, Huang X, Ouyang P, Lai W, Shi C. Identification and screening of effective protective antigens for channel catfish against Streptococcus iniae. Oncotarget 2018; 8:30793-30804. [PMID: 28415641 PMCID: PMC5458168 DOI: 10.18632/oncotarget.16475] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 03/13/2017] [Indexed: 11/25/2022] Open
Abstract
Vaccination is a potential approach for prevention and control of disease in fish. The use of genetically engineered vaccines is an effective method and a green intervention to control bacterial infection in aquaculture. However, efforts to develop these vaccines are limited by the lack of conserved protective antigens. In this study, three candidate immunogens (Srr, NeuA, and Hsp) of the pathogenic Streptococcus iniae strain DGX07 isolated from diseased channel catfish were identified and analyzed. Molecular cloning, expression, and purification of candidate antigen genes were carried out to obtain the candidate immunogens in the form of recombinant subunit vaccines. Western blotting was performed to evaluate immunogenicity in vitro and channel catfish were vaccinated by intraperitoneal injection and the specific antibody titers and relative percent of survival were determined to evaluate immune protection in vivo. The results showed that these three candidate immunogens were expressed correctly as recombinant proteins fused with His tags, with molecular weights of 70 kDa for Srr, 86 kDa for NeuA, and 51 kDa for Hsp, respectively. Moreover, each immunogen was predicted to be located either extracellularly or on the surface of S. iniae, and were able to offer protection against S. iniae infection in the form of recombinant subunit vaccines with adjuvant ISA763, especially Srr, with a relative percent of survival of 70% for Srr, 55% for NeuA, and 50% for Hsp, respectively.
Collapse
Affiliation(s)
- Yajun Wang
- Department of Basic Veterinary, Sichuan Agricultural University, Chengdu, Sichuan, China.,Pearl River Fishery Research Institute, Chinese Academy of Fishery Science, Guangzhou, China
| | - Erlong Wang
- Department of Basic Veterinary, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Yang He
- Department of Basic Veterinary, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Kaiyu Wang
- Department of Basic Veterinary, Sichuan Agricultural University, Chengdu, Sichuan, China.,Key Laboratory of Animal Disease and Human Health of Sichuan Province, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Qian Yang
- Department of Basic Veterinary, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Jun Wang
- Department of Basic Veterinary, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Yi Geng
- Department of Basic Veterinary, Sichuan Agricultural University, Chengdu, Sichuan, China.,Key Laboratory of Animal Disease and Human Health of Sichuan Province, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Defang Chen
- Department of Aquaculture, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Xiaoli Huang
- Department of Aquaculture, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Ping Ouyang
- Department of Basic Veterinary, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Weimin Lai
- Department of Basic Veterinary, Sichuan Agricultural University, Chengdu, Sichuan, China
| | - Cunbin Shi
- Pearl River Fishery Research Institute, Chinese Academy of Fishery Science, Guangzhou, China
| |
Collapse
|
8
|
Molinos-Albert LM, Clotet B, Blanco J, Carrillo J. Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target. Front Immunol 2017; 8:1154. [PMID: 28970835 PMCID: PMC5609547 DOI: 10.3389/fimmu.2017.01154] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Accepted: 08/31/2017] [Indexed: 12/12/2022] Open
Abstract
Broadly neutralizing antibodies (bNAbs) targeting conserved regions within the human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein (Env) can be generated by the human immune system and their elicitation by vaccination will be a key point to protect against the wide range of viral diversity. The membrane proximal external region (MPER) is a highly conserved region within the Env gp41 subunit, plays a major role in membrane fusion and is targeted by naturally induced bNAbs. Therefore, the MPER is considered as an attractive vaccine target. However, despite many attempts to design MPER-based immunogens, further study is still needed to understand its structural complexity, its amphiphilic feature, and its limited accessibility by steric hindrance. These particular features compromise the development of MPER-specific neutralizing responses during natural infection and limit the number of bNAbs isolated against this region, as compared with other HIV-1 vulnerability sites, and represent additional hurdles for immunogen development. Nevertheless, the analysis of MPER humoral responses elicited during natural infection as well as the MPER bNAbs isolated to date highlight that the human immune system is capable of generating MPER protective antibodies. Here, we discuss the recent advances describing the immunologic and biochemical features that make the MPER a unique HIV-1 vulnerability site, the different strategies to generate MPER-neutralizing antibodies in immunization protocols and point the importance of extending our knowledge toward new MPER epitopes by the isolation of novel monoclonal antibodies. This will be crucial for the redesign of immunogens able to skip non-neutralizing MPER determinants.
Collapse
Affiliation(s)
- Luis M Molinos-Albert
- IrsiCaixa AIDS Research Institute, Institut de Recerca Germans Trias i Pujol (IGTP), Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - Bonaventura Clotet
- IrsiCaixa AIDS Research Institute, Institut de Recerca Germans Trias i Pujol (IGTP), Germans Trias i Pujol University Hospital, Barcelona, Spain.,Universitat de Vic - Universitat Central de Catalunya, Barcelona, Spain
| | - Julià Blanco
- IrsiCaixa AIDS Research Institute, Institut de Recerca Germans Trias i Pujol (IGTP), Germans Trias i Pujol University Hospital, Barcelona, Spain.,Universitat de Vic - Universitat Central de Catalunya, Barcelona, Spain
| | - Jorge Carrillo
- IrsiCaixa AIDS Research Institute, Institut de Recerca Germans Trias i Pujol (IGTP), Germans Trias i Pujol University Hospital, Barcelona, Spain
| |
Collapse
|
9
|
Abstract
In 2009, Dimitrov's group reported that the inferred germline (iGL) forms of several HIV-1 broadly neutralizing antibodies (bNAbs) did not display measurable binding to a recombinant gp140 Env protein (derived from the dual-tropic 89.6 virus), which was efficiently recognized by the mature (somatically mutated) antibodies. At that time, a small number of bNAbs were available, but in the following years, the implementation of high-throughput B-cell isolation and sequencing assays and of screening methodologies facilitated the isolation of greater numbers of bNAbs from infected subjects. Using these newest bNAbs, and a wide range of diverse recombinant Envs, we and others confirmed the observations made by Dimitrov's group. The results from these studies created a paradigm shift in our collective thinking as to why recombinant Envs are ineffective in eliciting bNAbs and has led to the "germline-targeting" immunization approach. Here we discuss this approach in detail: what has been done so far, the advantages and limitations of the current germline-targeting immunogens and of the animal models used to test them, and we conclude with a few thoughts about future directions in this area of research.
Collapse
Affiliation(s)
- Leonidas Stamatatos
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.,Department of Global Health, University of Washington, Seattle, WA, USA
| | - Marie Pancera
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Andrew T McGuire
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| |
Collapse
|
10
|
Janahi EM, Dhasmana A, Srivastava V, Sarangi AN, Raza S, Arif JM, Bhatt MLB, Lohani M, Areeshi MY, Saxena AM, Haque S. In silico CD4+, CD8+ T-cell and B-cell immunity associated immunogenic epitope prediction and HLA distribution analysis of Zika virus. EXCLI J 2017; 16:63-72. [PMID: 28435428 PMCID: PMC5379118 DOI: 10.17179/excli2016-719] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/20/2016] [Accepted: 01/02/2017] [Indexed: 12/29/2022]
Abstract
Zika virus (ZIKV) is a mosquito-borne flavivirus distributed all over Africa, South America and Asia. The infection with the virus may cause acute febrile sickness that clinically resembles dengue fever, yet there is no vaccine, no satisfactory treatment, and no means of evaluating the risk of the disease or prognosis in the infected people. In the present study, the efficacy of the host's immune response in reducing the risk of infectious diseases was taken into account to carry out immuno-informatics driven epitope screening strategy of vaccine candidates against ZIKV. In this study, HLA distribution analysis was done to ensure the coverage of the vast majority of the population. Systematic screening of effective dominant immunogens was done with the help of Immune Epitope & ABCPred databases. The outcomes suggested that the predicted epitopes may be protective immunogens with highly conserved sequences and bear potential to induce both protective neutralizing antibodies, T & B cell responses. A total of 25 CD4+ and 16 CD8+ peptides were screened for T-cell mediated immunity. The predicted epitope "TGLDFSDLYYLTMNNKHWLV" was selected as a highly immunogenic epitope for humoral immunity. These peptides were further screened as non-toxic, immunogenic and non-mutated residues of envelop viral protein. The predicted epitope could work as suitable candidate(s) for peptide based vaccine development. Further, experimental validation of these epitopes is warranted to ensure the potential of B- and T-cells stimulation for their efficient use as vaccine candidates, and as diagnostic agents against ZIKV.
Collapse
Affiliation(s)
- Essam Mohammed Janahi
- Department of Biology, College of Science, University of Bahrain, P.O. Box 32038, Kingdom of Bahrain
| | - Anupam Dhasmana
- Research Cell, Amity University Lucknow Campus, Lucknow-226028, UP, India.,Department of Radiotherapy, King George Medical University, Lucknow-226003, UP, India
| | | | - Aditya Narayan Sarangi
- Biomedical Informatics Centre, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow-226014, UP, India
| | - Sana Raza
- Department of Radiotherapy, King George Medical University, Lucknow-226003, UP, India.,Department of Biosciences, Integral University, Lucknow-226026, UP, India
| | - Jamal M Arif
- Department of Biochemistry, University of Hail, Hail-2440, Saudi Arabia
| | | | - Mohtashim Lohani
- Department of Radiotherapy, King George Medical University, Lucknow-226003, UP, India.,Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan-45142, Saudi Arabia
| | - Mohammed Yahya Areeshi
- Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan-45142, Saudi Arabia
| | | | - Shafiul Haque
- Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan-45142, Saudi Arabia.,Department of Biosciences, Jamia Millia Islamia (A Central University), New Delhi-110025, India
| |
Collapse
|
11
|
Sanders M, Guo Y, Iyer A, García YR, Galvita A, Heyerick A, Deforce D, Risseeuw MDP, Van Calenbergh S, Bracke M, Eremin S, Madder A, De Saeger S. An immunogen synthesis strategy for the development of specific anti-deoxynivalenol monoclonal antibodies. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2014; 31:1751-9. [PMID: 25230728 DOI: 10.1080/19440049.2014.955887] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
An immunogen synthesis strategy was designed to develop anti-deoxynivalenol (DON) monoclonal antibodies with low cross-reactivity against structurally similar trichothecenes. A total of eight different DON immunogens were synthesised, differing in the type and position of the linker on the DON molecule. After immunisation, antisera from mice immunised with different DON immunogens were checked for the presence of relevant antibodies. Then, both homologous and heterologous enzyme-linked immunosorbent assays (ELISAs) were performed for hybridoma screening. Finally, three monoclonal antibodies against DON and its analogues were generated. In addition, monoclonal antibody 13H1 could recognise DON and its analogues in the order of HT-2 toxin > 15-acetyldeoxynivalenol (15-ADON) > DON, with IC₅₀ ranging from 1.14 to 2.13 µg ml⁻¹. Another monoclonal antibody 10H10 manifested relatively close sensitivities to DON, 3-acetyldeoxynivalenol (3-ADON) and 15-ADON, with IC₅₀ values of 22, 15 and 34 ng ml⁻¹, respectively. Using an indirect ELISA format decreases the 10H10 sensitivity to 15-ADON with 92%. A third monoclonal antibody 2A9 showed to be very specific and sensitive to 3-ADON, with IC₅₀ of 0.38 ng ml⁻¹. Using both 2A9 and 10H10 monoclonal antibodies allows determining sole DON contamination.
Collapse
Affiliation(s)
- Melanie Sanders
- a Laboratory of Food Analysis , Ghent University , Ghent , Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Costa SJ, Silva P, Almeida A, Conceição A, Domingues L, Castro A. A novel adjuvant-free H fusion system for the production of recombinant immunogens in Escherichia coli: Its application to a 12 kDa antigen from Cryptosporidium parvum. Bioengineered 2013; 4:413-9. [PMID: 23941978 PMCID: PMC3937203 DOI: 10.4161/bioe.26003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
The production of recombinant antigens in Escherichia coli and specific polyclonal antibodies for diagnosis and therapy is still a challenge for world-wide researchers. Several different strategies have been explored to improve both antigen and antibody production, all of them depending on a successful expression and immunogenicity of the antigen. Gene fusion technology attempted to address these challenges: fusion partners have been applied to optimize recombinant antigen production in E. coli, and to increase protein immunogenicity. Taking a 12-kDa surface adhesion antigen from Cryptosporidium parvum (CP12) by example, the novel H fusion partner was presented in this work as an attractive option for the development of recombinant immunogens and its adjuvant-free immunization. The H tag (of only 1 kDa) efficiently triggered a CP12-specific immune response, and it also improved the immunization procedure without requiring co-administration of adjuvants. Moreover, polyclonal antibodies raised against the HCP12 fusion antigen detected native antigen structures displayed on the surface of C. parvum oocysts. The H tag proved to be an advanced strategy and promising technology for the diagnosis and therapy of C. parvum infections in animals and humans, allowing a rapid and simple recombinant production of the CP12 antigen.
Collapse
Affiliation(s)
- Sofia J Costa
- Institute for Biotechnology and Bioengineering; Centre of Biological Engineering; Universidade do Minho, Campus de Gualtar; Braga, Portugal; Instituto Nacional de Saúde Dr Ricardo Jorge; Porto, Portugal; Escola Superior Agrária de Coimbra; Coimbra, Portugal; Instituto de Ciências e Tecnologias Agrárias e Agroalimentares da Universidade do Porto; Porto Portugal; Hitag Biotechnology, Lda.; Biocant-Parque Tecnológico de Cantanhede; Cantanhede, Portugal
| | - Pedro Silva
- Instituto Nacional de Saúde Dr Ricardo Jorge; Porto, Portugal; Escola Superior Agrária de Coimbra; Coimbra, Portugal
| | - André Almeida
- Instituto de Ciências e Tecnologias Agrárias e Agroalimentares da Universidade do Porto; Porto Portugal; Hitag Biotechnology, Lda.; Biocant-Parque Tecnológico de Cantanhede; Cantanhede, Portugal
| | | | - Lucília Domingues
- Institute for Biotechnology and Bioengineering; Centre of Biological Engineering; Universidade do Minho, Campus de Gualtar; Braga, Portugal
| | - António Castro
- Instituto Nacional de Saúde Dr Ricardo Jorge; Porto, Portugal
| |
Collapse
|
13
|
Abstract
A recent development in the production of experimental vaccines has been the use of the smallpox vaccine virus (vaccinia virus) as a carrier (vector) of the genes (immunogenes) which code for the protection-inducing proteins (immunogens) of unrelated viruses. The potential of these vector vaccines lies in the hope that such a vaccine would be cheaper, safer and/or more effective than existing vaccines to some pathogens. Vaccinia virus as a vector has attracted most attention to date because: several immunogenes can be inserted into its genome without destroying its infectivity; the immunogens appear to be produced normally; vaccinia virus has been used highly successfully to eradicate smallpox; and it has a wide host-range and thus might find veterinary as well as human medical application. Experimental vaccines, successfully tested in animals, have been prepared using immunogenes from influenza virus, hepatitis B virus and herpes simplex virus. Apathogenic enteric bacteria have some potential as vectors, most probably against enteric pathogens, although the potential of viral vectors is likely to be realized first. Parasitic worms and protozoa devastate millions of people. When the immunogens of these organisms have been identified there will be added impetus to investigate the potential of vector vaccines against these pathogens.
Collapse
|